A Pilot Study To Assess The Utility Of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) In The Pre-Operative Evaluation Of Patients With Primary And Recurrent Breast Carcinoma
OBJECTIVES:
- Determine the sensitivity, specificity, and accuracy of fludeoxyglucose F 18 (FDG)
positron emission tomography (PET) as compared to conventional imaging in determining
the extent of disease in women with primary or recurrent breast cancer.
- Determine how often clinical management and operative intervention plans for patients
are altered based on these FDG-PET scan findings.
- Determine whether FDG-PET results in more accurate detection of disease in these
patients.
OUTLINE: Patients receive fludeoxyglucose F 18 IV. Approximately 1 hour later, patients
undergo positron emission tomography imaging. Some patients may undergo a repeat scan in 4-6
months.
PROJECTED ACCRUAL: (50 with primary disease and 50 with recurrent disease) will be accrued
for this study within 1-2 years.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Determine the sensitivity, specificity, and accuracy
2 years
No
Elisa Rush Port, MD
Study Chair
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
01-134
NCT00039286
October 2001
February 2009
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |